Segments

3 Months Ended

Mar. 31, 2013

Segments [Abstract]

Segments

8.  Segments

ATMI has two reportable operating segments, Microelectronics and LifeSciences. Our Chief Executive Officer regularly reviews financial information which separately identifies each segment’s results.   

The Microelectronics business unit sells high-purity materials and materials delivery systems for integrated circuit and flat-panel display manufacturing.  Microelectronics products consist of ATMI’s patented Safe Delivery Source® (“SDS”) solutions to deliver ion implant gases, copper materials for plating, post-etch cleans, post-CMP cleans and deposition, and high-purity liquid materials packaging solutions.  Microelectronics products represent the largest portion of ATMI’s business and development activities.  The principal drivers for this market are technical performance, yield improvement, time to market, cost, utilization of capital, and risk reduction.  The success of an electronic component or device is determined by the increased functionality it can deliver at an acceptable cost. 

The life sciences industry has been using disposable components like filters, connectors, and disposable storage bags for several years; however, as customers migrate toward processes which integrate disposable components into disposable systems, we see growing opportunities.  The LifeSciences business unit sells products that address an increasing number of critical process steps for biopharmaceutical manufacturing of vaccines, monoclonal antibodies, and cell therapy applications, including disposable mixers and bioreactors, both considered growth opportunities for ATMI.  This unit includes our Newform™ products and Integrity® suite of single-use technology mixers, bioreactors and bioprocess vessels.

The Company evaluates performance and allocates resources based on profit or loss from operations.  The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies.  

	Revenue (1)
	Three Months Ended
	March 31,
	2013		2012
Microelectronics	$	88,111	$	83,465
LifeSciences		11,281		9,109
All Other		15		-
Total Consolidated	$	99,407	$	92,574

	Operating income (loss)
	Three Months Ended
	March 31,
	2013		2012
Microelectronics	$	25,242	$	21,032
LifeSciences		(1,258)		(2,126)
All Other		(13,647)		(12,759)
Total Consolidated	$	10,337	$	6,147

⁽¹⁾ Intersegment sales were not significant for the three month periods ended March 31, 2013 and 2012.